REGENXBIO Inc(RB0)

Description: REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy. It also develops RGX-121 for the treatment of mucopolysaccharidosis type II that is in Phase III clinical trial; RGX-111 for treating mucopolysaccharidosis type I; RGX-181 for the treatment of late infantile neuronal ceroid lipofuscinosis type II; and RGX-381 to treat the ocular manifestations of CLN2 disease. In addition, the company licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies. Further, it has a collaboration and license agreement with AbbVie Global Enterprises Ltd. to develop ABBV-RGX-314 outside the United States. REGENXBIO Inc. was incorporated in 2008 and is headquartered in Rockville, Maryland.

---

Keywords: Biotechnology Pharmaceutical Rare Diseases Gene Therapy Molecular Biology Diabetic Retinopathy Wet Age Related Macular Degeneration Muscular Dystrophy Applied Genetics Gene Delivery Lipid Storage Disorders Mucopolysaccharidosis Adeno Associated Virus Hunter Syndrome Rgx

---

Home Page: www.regenxbio.com

9804 Medical Center Drive
Rockville, MD 20850
United States
Phone: 240 552 8181

---

Officers

Exchange: F

Country: DE : Germany

Currency: Euro (€)